ES2618489T3 - Composiciones farmacéuticas combinadas y usos de las mismas - Google Patents

Composiciones farmacéuticas combinadas y usos de las mismas Download PDF

Info

Publication number
ES2618489T3
ES2618489T3 ES12779459.2T ES12779459T ES2618489T3 ES 2618489 T3 ES2618489 T3 ES 2618489T3 ES 12779459 T ES12779459 T ES 12779459T ES 2618489 T3 ES2618489 T3 ES 2618489T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
heteroaryl
alkynyl
nr31r32
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12779459.2T
Other languages
English (en)
Spanish (es)
Inventor
Yi Liu
Pingda Ren
Katayoun JESSEN
Xin Guo
Christian Rommel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intellikine LLC
Original Assignee
Intellikine LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellikine LLC filed Critical Intellikine LLC
Application granted granted Critical
Publication of ES2618489T3 publication Critical patent/ES2618489T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12779459.2T 2011-05-04 2012-05-04 Composiciones farmacéuticas combinadas y usos de las mismas Active ES2618489T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482568P 2011-05-04 2011-05-04
US201161482568P 2011-05-04
PCT/US2012/036688 WO2012151562A1 (en) 2011-05-04 2012-05-04 Combination pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
ES2618489T3 true ES2618489T3 (es) 2017-06-21

Family

ID=47108075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12779459.2T Active ES2618489T3 (es) 2011-05-04 2012-05-04 Composiciones farmacéuticas combinadas y usos de las mismas

Country Status (7)

Country Link
US (2) US20140357651A1 (enExample)
EP (1) EP2705181B1 (enExample)
JP (1) JP6047149B2 (enExample)
CN (1) CN103703174B (enExample)
CA (1) CA2836769C (enExample)
ES (1) ES2618489T3 (enExample)
WO (1) WO2012151562A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2836769C (en) 2011-05-04 2018-11-13 Intellikine, Llc The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder
CN103796655A (zh) * 2011-05-06 2014-05-14 加利福尼亚大学董事会 多囊性疾病的治疗
EP2976086B1 (en) * 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015002766A1 (en) * 2013-07-02 2015-01-08 Nikolai Khodarev Anti-tumor therapy
EP3473630B1 (en) * 2014-07-02 2021-01-13 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2016040806A1 (en) 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
WO2016064957A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
US10023576B2 (en) 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
US10532226B2 (en) * 2014-12-24 2020-01-14 The University Of North Carolina At Chapel Hill Combined local delivery of therapeutic agents using interventional devices and radiation
PT3436461T (pt) 2016-03-28 2024-01-23 Incyte Corp Compostos de pirrolotriazina como inibidores de tam
ES2886587T3 (es) 2016-04-15 2021-12-20 Cancer Research Tech Ltd Compuestos heterocíclicos como inhibidores de la quinasa RET
EP4104837A3 (en) 2016-04-15 2023-04-26 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
WO2018067943A1 (en) * 2016-10-07 2018-04-12 Abraxis Bioscience, Llc Methods of treating biliary tract cancer
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
FR3075795A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
MX2020011564A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina unidos a c26 como inhibidores de mtor.
US20190336609A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
JP7668536B2 (ja) * 2020-02-07 2025-04-25 範行 東 細胞周期のｇ１期初期制御剤
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
WO2021168283A1 (en) * 2020-02-19 2021-08-26 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
US20240082249A1 (en) 2022-05-25 2024-03-14 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US20090274698A1 (en) * 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
JP2012506898A (ja) * 2008-10-31 2012-03-22 ノバルティス アーゲー ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤とｍＴＯＲ阻害剤との併用剤
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
CA2836769C (en) 2011-05-04 2018-11-13 Intellikine, Llc The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder

Also Published As

Publication number Publication date
EP2705181A1 (en) 2014-03-12
CA2836769C (en) 2018-11-13
CN103703174A (zh) 2014-04-02
CN103703174B (zh) 2017-05-10
EP2705181A4 (en) 2014-10-08
JP2014513138A (ja) 2014-05-29
JP6047149B2 (ja) 2016-12-21
WO2012151562A1 (en) 2012-11-08
US10172858B2 (en) 2019-01-08
HK1195793A1 (en) 2014-11-21
US20140357651A1 (en) 2014-12-04
US20160287595A1 (en) 2016-10-06
CA2836769A1 (en) 2012-11-08
EP2705181B1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
ES2618489T3 (es) Composiciones farmacéuticas combinadas y usos de las mismas
JP6114296B2 (ja) 複数の医薬品を使用した治療レジメン
ES2709108T3 (es) Compuestos heterocíclicos y usos de los mismos
CN103491962B (zh) 激酶抑制剂的组合及其用途
JP6126615B2 (ja) キナーゼ阻害剤の組み合わせおよびそれらの使用
JP6130391B2 (ja) Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
JP2016512835A (ja) キナーゼ阻害剤の組み合わせ及びそれらの使用
WO2012154608A1 (en) Reactive mtor and pi3 kinase inhibitors and uses thereof
WO2012154610A1 (en) Reactive pi3k kinase inhibitors and uses thereof
HK1195793B (en) Combination pharmaceutical compositions and uses thereof
HK1236441A (en) Combination of kinase inhibitors and uses thereof
HK1236441A1 (zh) 激酶抑制劑的組合及其用途